Navigation Links
Alimera Sciences Secures $20 Million Debt Facility
Date:5/8/2013

rest is payable on the balance of eligible accounts financed at the rate of 2.75% above SVB's most recently announced "prime rate." The maturity dates for the line of credit and the term loan are June 30, 2015 and October 31, 2016, respectively.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera's commercial plans for ILUVIEN in the European Union and Alimera's financing needs. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the European Union, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2012, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may also be
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
2. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
3. Alimera Sciences Names European Management Team
4. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
5. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
6. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
7. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... 2014 For the first time, cardiac surgeons, ... of the SynCardia temporary Total Artificial Heart in a ... on the Journal of Visualized Experiments website. ... on the SynCardia Total Artificial Heart implantation   ... of the SynCardia Total Artificial Heart," a July 18, ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... Development of Intradigm,s ICS-283, PALO ALTO, ... developer of targeted, systemic RNA interference (RNAi),therapeutics, ... company,s,TargeTran(TM) delivery system is capable of delivering ... RNAs (siRNAs) that suppress,tumor-induced angiogenesis by silencing ...
... BiPar Sciences, Inc., a,privately held biopharmaceutical ... demonstrating that BSI-401 inhibited pancreatic cancer,cell growth ... and in combination with,oxaliplatin. BSI-401 is BiPar,s ... therapies known as PARP (poly-ADP-ribose polymerase) inhibitors. ...
Cached Medicine Technology:Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2
(Date:7/31/2014)... 31, 2014 LDM Global ( http://www.ldmglobal.com ... model that is simplified and predictable with fixed fees ... As a leading international provider of legal discovery management ... has become glaringly apparent that both the courts and ... budgets and the complex pricing structure that plagues the ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... 31, 2014 Setting goals for a fitness ... on successful tips to weight loss. Fitness on the Go ... 8 years, and has worked with 6000 customers on an ... had the chance to monitor why customers start exercising with ... long they stick to their program, whether or not they ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint that ... airway to quiet snoring. , Dawn M. of Utah shared ... husband by allowing them to share the same bedroom again. ... 15 years ago and I remember nights when it was so ... to head downstairs for any relief. As the years have gone ...
(Date:7/31/2014)... York, New York (PRWEB) July 31, 2014 ... to grow, as Bernstein Liebhard LLP notes that ... that it plans to voluntarily remove its power ... to a report from Bloomberg.com, the company said ... and benefits associated with the devices remain uncertain.* ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... pills and capsules that show a tendency in the standard ... a faster and potentially unsafe manner in patients who have ... proven safe with testing in people. That,s the conclusion ... of ACS, Molecular Pharmaceutics , a bi-monthly journal. ...
... WASHINGTON, Sept. 23 In the year since the crash ... concerns despite rising unemployment levels and ongoing economic uncertainty, according to ... In a poll surveying 2,160 adults conducted by Harris Interactive(R) between ... the economy caused stress in their lives, down from 82 percent ...
... , PRINCETON, N.J., Sept. 23 Bringing a new ... makers of Trojan(R) Brand Condoms recently introduced Trojan 2GO(R), a new ... new product, which is designed to stand-up to purses, wallets, pockets ... food, drug and convenience retail locations, making Trojan 2GO both easy ...
... NORTHRIDGE, Calif., Sept. 23 Today, Nature Made(R) ... Greatness(TM) contest. Nature Made is the nation,s best-selling brand ... mass and club channels. The company celebrates the inherent greatness ... challenged Americans to submit their personal stories of greatness as ...
... cyber-bullying and an increase in violence among young women will ... Professor Kerry Carrington, head of Queensland University of Technology,s School ... confirm, contrary to general academic opinion, young women are fast ... will present her findings, to be revealed in her book ...
... Mich. Immune therapies have been explored as a way ... from the University of Michigan Comprehensive Cancer Center suggests that ... critical immune system cells. The study was done ... in the lab before being available for humans. But the ...
Cached Medicine News:Health News:Interview Alert: At Anniversary of Financial Meltdown, Psychologists Notice Downward Trends in Economic Stress 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 2Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 3Health News:Makers of Trojan(R) Brand Condoms Introduce Trojan 2GO(R), a Unique, Portable, Protective and Discreet Packaging for Condoms 4Health News:National 'Greatness' Contest Winners Announced 2Health News:National 'Greatness' Contest Winners Announced 3Health News:Girls' violence on the rise 2Health News:Study looks at using the immune system to reduce prostate cancer risk 2
... Tegagel hydrogel wound filler and Tegagel ... amorphous hydrogel dressings specially formulated to ... has been shown to enhance wound ... meets clinical needs for management of ...
... and Tegagel hydrogel wound filler with ... formulated to help provide a moist ... enhance wound healing. The unique, viscous, ... management of non-draining, minimally draining and ...
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
... Esteem™ External Vacuum Therapy System restores sexual ... men. Non-invasive and low cost vacuum therapy, ... desirable outcome", makes it the ideal therapy ... Therapy System causes penile rigidity that can ...
Medicine Products: